ANCA Vasculitis Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "ANCA Vasculitis Pipeline Insight 2025" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in ANCA Vasculitis pipeline landscape. It covers the ANCA Vasculitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ANCA Vasculitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the ANCA Vasculitis Pipeline. Dive into DelveInsight's comprehensive report today! @ ANCA Vasculitis Pipeline Outlook- https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the ANCA Vasculitis Pipeline Report
• In May 2025, Amgen announced a study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
• In May 2025, Novartis Pharmaceuticals announced a study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL.
• In May 2025, NS Pharma Inc. announced a study is to investigate the efficacy and safety of NS229 compared with placebo over a 28-week study treatment period in subjects with Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving background corticosteroid therapy with or without Mepolizumab/Benralizumab therapy. During the treatment period corticosteroid dose will be tapered.
• DelveInsight's ANCA Vasculitis Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for ANCA Vasculitis treatment.
• The leading ANCA Vasculitis Companies such as Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co. Ltd. and others.
• Promising ANCA Vasculitis Pipeline Therapies such as Avacopan, Prednisone, Cyclophosphamide, BDB-001 injection, Glucocorticoids, Rituximab, Mycophenolate Mofetil, Cyclophosphamide, and others.

Stay ahead with the most recent pipeline outlook for ANCA Vasculitis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ ANCA Vasculitis Treatment Drugs- https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

ANCA Vasculitis Emerging Drugs Profile
• Abatacept: Bristol-Myers Squibb
Abatacept is a selective T-cell co-stimulation modulator. Abatacept binds to CD80 and CD86 receptors on antigen-presenting cells (APCs), which are essential for T-cell activation. This binding blocks the interaction between CD80/CD86 and CD28, thereby inhibiting the delivery of the second co-stimulatory signal required for optimal T-cell activation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ANCA Vasculitis.

• Sparsentan : Travere Therapeutics
Sparsentan is a dual endothelin and angiotensin II receptor antagonist used to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Sparsentan acts as a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R), which are involved in the pathogenesis of IgAN. It selectively blocks the action of endothelin-1 (ET-1) and angiotensin II (Ang II) at their respective receptors, thereby reducing proteinuria. The drug is currently in Phase II of clinical trial evaluation for the treatment of ANCA Associated Vasculitis.

The ANCA Vasculitis Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of ANCA Vasculitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ANCA Vasculitis Treatment.
• ANCA Vasculitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• ANCA Vasculitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ANCA Vasculitis market

Explore groundbreaking therapies and clinical trials in the ANCA Vasculitis Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New ANCA Vasculitis Drugs- https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

ANCA Vasculitis Companies
Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co. Ltd. and others.

ANCA Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

ANCA Vasculitis Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of ANCA Vasculitis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ ANCA Vasculitis Market Drivers and Barriers- https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the ANCA Vasculitis Pipeline Report
• Coverage- Global
• ANCA Vasculitis Companies- Bristol-Myers Squibb, Travere Therapeutics, Novartis Pharmaceuticals, NS Pharma, Staidson Biopharmaceuticals Co. Ltd. and others.
• ANCA Vasculitis Pipeline Therapies- Avacopan, Prednisone, Cyclophosphamide, BDB-001 injection, Glucocorticoids, Rituximab, Mycophenolate Mofetil, Cyclophosphamide, and others.
• ANCA Vasculitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• ANCA Vasculitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on ANCA Vasculitis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ ANCA Vasculitis Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/anca-vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. ANCA Vasculitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. ANCA Vasculitis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Abatacept: Bristol-Myers Squibb
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Sparsentan : Travere Therapeutics
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. ANCA Vasculitis Key Companies
21. ANCA Vasculitis Key Products
22. ANCA Vasculitis- Unmet Needs
23. ANCA Vasculitis- Market Drivers and Barriers
24. ANCA Vasculitis- Future Perspectives and Conclusion
25. ANCA Vasculitis Analyst Views
26. ANCA Vasculitis Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2025

Radiation retinopathy market- https://www.delveinsight.com/sample-request/radiation-retinopathy-market
Immune checkpoints activators market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Cystic fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Palmoplantar pustulosis market- https://www.delveinsight.com/report-store/palmoplantar-pustulosis-market
Smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Tay-Sachs market- https://www.delveinsight.com/report-store/tay-sachs-disease-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market
Open angle glaucoma market- https://www.delveinsight.com/report-store/glaucoma-market
Acute myeloid leukemia market- https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market
Asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Bone growth stimulators market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Cardiogenic shock market- https://www.delveinsight.com/report-store/cardiogenic-shock-market
Pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
Pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
Pelizaeus-merzbacher disease market- https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
Peritoneal carcinomatosis market- https://www.delveinsight.com/report-store/peritoneal-carcinomatosis-pc-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.